Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of subjects treated with gene-modified T cells
NL-OMON54564Phase 2Recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in plasma cell neoplasm and hematopoietic malignancies, sponsored by Celgene Corporation. Primary endpoints: Delayed adverse events and new clinical conditions, Long-term persistence of gene-modified T cells and 3 more. Started Jan 2022; status: recruiting.
02
Conditions
plasma cell neoplasmhematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON54564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54564.